Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus.
作者信息
Raza Hunain, Bhutta Muhammad E, Siddique Muhammad H
机构信息
Islamic International Medical College, Riphah International University, Rawalpindi, Pakistan.
出版信息
Sultan Qaboos Univ Med J. 2024 Aug;24(3):418-419. doi: 10.18295/squmj.8.2024.050. Epub 2024 Aug 29.
Abstract
摘要
相似文献
1
Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus.
Sultan Qaboos Univ Med J. 2024 Aug;24(3):418-419. doi: 10.18295/squmj.8.2024.050. Epub 2024 Aug 29.
2
Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
Prescrire Int. 2013 May;22(138):121.
3
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845.
4
Vildagliptin: a review of its use in type 2 diabetes mellitus.
Drugs. 2010 Nov 12;70(16):2089-112. doi: 10.2165/11206370-000000000-00000.
5
Translating science into clinical practice: focus on vildagliptin in combination with metformin.
Diabetes Obes Metab. 2009 May;11 Suppl 2:18-26. doi: 10.1111/j.1463-1326.2008.01030.x.
6
Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Diabetes Obes Metab. 2014 May;16(5):403-9. doi: 10.1111/dom.12229. Epub 2013 Dec 2.
7
Update: vildagliptin for the treatment of Type 2 diabetes.
Expert Opin Investig Drugs. 2008 Jan;17(1):105-13. doi: 10.1517/13543784.17.1.105.
8
Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Diabetes Obes Metab. 2012 Aug;14(8):737-44. doi: 10.1111/j.1463-1326.2012.01593.x. Epub 2012 Apr 1.
9
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Diabet Med. 2010 Mar;27(3):318-26. doi: 10.1111/j.1464-5491.2010.02938.x.
10
Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study.
Cardiovasc Diabetol. 2013 Aug 19;12:118. doi: 10.1186/1475-2840-12-118.
本文引用的文献
1
Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus: An open-label comparative study.
Sultan Qaboos Univ Med J. 2024 May;24(2):243-249. doi: 10.18295/squmj.1.2024.006. Epub 2024 May 27.
2
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.
Diabetes Obes Metab. 2023 Jan;25(1):3-17. doi: 10.1111/dom.14831. Epub 2022 Aug 31.
3
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
4
Prevalence of dyslipidemia in adult Indian diabetic patients: A cross sectional study (SOLID).
Indian J Endocrinol Metab. 2014 Sep;18(5):642-7. doi: 10.4103/2230-8210.139220.
5
Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Diabetes Obes Metab. 2015 Jan;17(1):94-7. doi: 10.1111/dom.12391. Epub 2014 Nov 3.
Zotero 插件